Ursodeoxycholic Acid Ameliorates Pain Severity and Cartilage Degeneration in Monosodium Iodoacetate-Induced Osteoarthritis in Rats

Su-Jin Moon1#, Jeong-Hye Jeong2#, Joo Yeon Jhun2, Eun Ji Yang2, Jun-Ki Min1, Jong Young Choi3 and Mi-La Cho2*

1Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 2The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, 3Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 137-040, Korea

Osteoarthritis (OA) is a degenerative joint disease characterized by a progressive loss of cartilage. And, increased oxidative stress plays a relevant role in the pathogenesis of OA. Ursodeoxycholic acid (UDCA) is a used drug for liver diseases known for its free radical-scavenging property. The objectives of this study were to investigate the in vivo effects of UDCA on pain severity and cartilage degeneration using an experimental OA model and to explore its mode of actions. OA was induced in rats by intra-articular injection of monosodium iodoacetate (MIA) to the knee. Oral administration UDCA was initiated on the day of MIA injection. Limb nociception was assessed by measuring the paw withdrawal latency and threshold. Samples were analyzed macroscopically and histologically. Immunohistochemistry was used to investigate the expression of interleukin-1β (IL-1β), IL-6, nitrotyrosine and inducible nitric oxide synthase (iNOS) in knee joints. UDCA showed an antinociceptive property and attenuated cartilage degeneration. OA rats given oral UDCA significantly exhibited a decreased number of osteoclasts in subchondral bone legion compared with the vehicle-treated OA group. UDCA reduced the expression of IL-1β, IL-6, nitrotyrosine and iNOS in articular cartilage. UDCA treatment significantly attenuated the mRNA expression of matrix metalloproteinase-3 (MMP-3), -13, and ADAMTS5 in IL-1β-stimulated human OA chondrocytes. These results show the inhibitory effects of UDCA on pain production and cartilage degeneration in experimentally induced OA. The chondroprotective properties of UDCA were achieved by suppressing oxidative damage and inhibiting catabolic factors that are implicated in the pathogenesis of cartilage damage in OA.

INTRODUCTION

Osteoarthritis (OA), the most common form of arthritis, is a complex joint disease that produces debilitating chronic pain in affecting individuals. OA is characterized by progressive cartilage loss, osteophyte formation, and changes of subchondral bone. OA tends to worsen over time as cartilage wears away. However, there are increasing evidences supporting that inflammation may be implicated in the development and progression of OA, even in the early stage (1). Proinflammatory cytokines such as interleukin-1β (IL-1β) and IL-6 play critical roles in disturbed homeostasis in OA cartilage (2,3). Until now, treatment targets have mainly focused
on reducing pain. Relatively, disease modifying anti-OA drugs (DMOADs) are still lacking.

Oxidative stress implies a disturbed cell state in which reactive oxygen species (ROS) production exceeds the neutralization capacity. Chronic oxidative stress underlies the pathophysiology of several autoimmune diseases including rheumatoid arthritis (RA) and Behçet’s disease (4, 5). Numerous studies have demonstrated that oxidative stress has been implicated in OA similar to RA, albeit to a lesser degree (6). In conjunction with metalloproteinases, ROS can work to degrade matrix components, ROS directly oxidizes transcriptional factors, intracellular and extracellular components resulting in cell death and matrix components breakdown (7-9). Previous reports have shown that ROS scavengers can attenuate the degradation of articular cartilage (10).

Ursodeoxycholic acid (UDCA) is a naturally occurring dihydroxy hydrophilic bile acid that is currently used to treat various liver diseases including primary biliary cirrhosis (11). Previous reports suggested that immunomodulation and anti-inflammatory effects are implicated in the mechanisms of the drug (12). And, the action of antioxidant of UDCA may contribute to its hepatoprotection properties (13-15). To our knowledge, the effect of UDCA has not been investigated in an animal model of OA or human OA. Given the potential role of oxidative stress in OA pathogenesis, the effects of UDCA on pain production and cartilage degeneration in a monosodium iodoacetate (MIA)-induced OA rat model was investigated.

MATERIALS AND METHODS

Animals

Male Wistar rats weighing 140~230 g (6 weeks of age) at the start of the experiment were purchased from Central Lab, Animal Inc. (Seoul, South Korea). The animals were housed three per cage in a room with controlled temperature conditions (21~22°C), controlled lighting (12-h light/12-h dark cycle) and access to sterile food and water. All animal procedures were approved by the Animal Research Ethics Committee at the Catholic University of Korea.

Induction of OA in the rat and treatment with UDCA

The animals were randomized and assigned to treatment groups prior to the start of the study. After anesthetization with isoflurane, rats were injected with 50 ml containing 3 mg of MIA (Sigma) using a 26.5-G needle inserted through the patellar ligament into the intra-articular space of the right knee. Control rats were injected with an equivalent volume of saline, UDCA was kindly provided by Daewoong Pharmaceutical Company (Seoul, Korea), UDCA dissolved in saline was administered orally every day. The vehicle-treated animals were given an equivalent volume of cotton seed oil solution. The dose of UDCA was 50 mg/kg of body weight.

Assessment of pain behavior

The MIA-treated rats were randomized to each experimental group. Nociceptive testing was performed using a dynamic plantar esthesiometer (Ugo Basile), an automated version of the von Frey hair assessment procedure, before the MIA injection (Day 0) and on the given day after MIA injection. The rats were placed on a metal mesh surface in an acrylic chamber in a temperature-controlled room (21~22°C) and allowed to rest for 15 min before testing. The touch stimulus unit was oriented beneath the animal, An adjustable angled mirror was used to place the stimulating microfilament (0.5-mm diameter) below the plantar surface of the hind paw. When the instrument was activated, a fine plastic monofilament advanced at a constant speed and touched the paw in the proximal metatarsal region, The filament exerted a gradual increasing force on the plantar surface, starting below the threshold of detection and increasing until the stimulus became painful indicated by the removal of its paw. The force required to elicit a paw withdrawal reflex was recorded automatically and measured in g. A maximum force of 50 g and a ramp speed of 20 s were used for all esthesiometry tests. Pain behavioral tests of secondary tactile allodynia were conducted prior to the UDCA administration.

Histological and immunohistochemical analyses

Histological changes were assessed to confirm the effect of UDCA on cartilage degeneration in the knee joints of OA rats. The animals were perfused via the ascending aorta with 10% neutral buffered formalin (pH 7.4). The knee joints, including the patella and joint capsule, were resected and kept in the same fixative for an additional 48 h at 4°C. The fixed specimens were decalcified with 5% formic acid decalifier for 6 days at 4°C. After decalcification, the specimens were embedded in paraffin, Standardized 7 μm serial sections were obtained at the medial and lateral midcondylar level in the sagittal plane and were stained with hematoxylin and eosin (HE), Safranin O-fast green, and toluidine blue to enable evaluation of proteoglycan content, Slides for immunohistochem-
Articular cartilage samples were obtained as surgical waste tissue and collagenase digestion to isolate primary chondrocytes from non-lesional areas, further minced, and subjected to passages within the first three passages. Cartilage was harvested during surgery. The isolated chondrocytes were used for experiments from 3 patients undergoing total knee replacement surgery. The isolated chondrocytes were used for experiments from 3 patients undergoing total knee replacement surgery.

The sections used for this project were collected under approval of the Seoul St. Mary’s Hospital (Seoul, Korea) IRB. Articular cartilage samples were obtained as surgical waste tissues from 3 patients undergoing total knee replacement surgery. The isolated chondrocytes were used for experiments within the first three passages. Cartilage was harvested from non-lesional areas, further minced, and subjected to pronase and collagenase digestion to isolate primary chondrocytes, similar to previously published Methods (16). Chondrocytes were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS. To activated chondrocyte conditions, the chondrocytes were stimulated with IL-1β (20 ng/ml) (R&D Systems) for 48 h. The cells were pretreated with UDCA for 2 h and then stimulated under the required activating conditions.

**Real-time polymerase chain reaction (RT-PCR)**

Messenger RNA (mRNA) was extracted using TRI Reagent (Molecular Research Center) according to the manufacturer’s instructions. Complementary DNA was synthesized using a SuperScript Reverse Transcription system (Takara), A LightCycler 2.0 instrument (sofware version 4.0; Roche Diagnostics) was used for PCR amplification. All reactions were performed with LightCycler FastStart DNA Master SYBR Green I (Takara) according to the manufacturer’s instructions. The following primers were used for human gen genes for MMP3, 5’CTC ACA GAC CTG ACT CGG TT-3’ (sense) and 5’-CAC GCC TGA AGG AGA AGA TG-3’ (antisense); for MMP13, 5’-CTA TGG TTC AGG AGA TG-3’ (sense) and 5’-AGA GTC TTG CCT GTA TCC TG-3’ (antisense); for ADAMTS5, 5’-TAT GAC AGG TGC GGA GTA TG-3’ (sense) and 5’TCTT AGG GCT AAA TAG GCA GT-3’ (antisense) and, for β-actin, 5’-GGG-CCT-CTA-GCA-AGA-GAT-TG-3’ (sense) and 5’TGT-GTT-GGG-GTA-CAG-GTC-TTT-G-3’ (antisense). Messenger RNA levels were normalized to that of β-actin. An ABI Prism 7700 sequence detection system (Applied Biosystems).

**MTT assay**

Cell viability was assessed with the MTT assay based on the ability of mitochondria of viable cells to convert soluble MTT into an insoluble purple formazan reaction product, MTT (Sigma) solution (5 mg/ml in Dulbecco’s modified Eagle’s medium (DMEM) without phenol red) was added to cells in tissue culture for 2 h. The MTT solution was aspirated, dimethyl sulfoxide (DMSO) was added (200 ml/each well of 12 well plate) to solubilize formazan and detection occurred by addition of 100 ml of the reaction mixture to a 96 well plate format and reading at optical density (O.D.) 540 nm. MTT assay results for the peripheral blood mononuclear cell were derived from two independent experiments, performed in duplicates.

**Statistical analysis**

The change of pain behavior is expressed as means±stand-
UDCA Attenuates OA Severity in MIA
Su-Jin Moon, et al.

IMMUNE NETWORK Vol. 14, No. 1: 45-53, February, 2014

Figure 1. Effects of UDCA on mechanical hyperalgesia in a model of MIA-induced OA rats. Rats were injected with 3 mg of MIA in the right knee. UDCA was administered orally every day for 14 days after MIA injection. Behavioral tests of mechanical hyperalgesia in MIA-injected rats treated with vehicle or UDCA were evaluated using a dynamic plantar aesthesiometer on day 14 (n=6 on each day for each group). The data are expressed as mean and error bars per group. PWL and PWT were conducted right before the administration of UDCA. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with the vehicle-treated OA group.

RESULTS

The effect of ursodeoxycholic acid on pain production in OA rats
Because pain is the predominant symptom of OA, the secondary tactile allodynia in MIA-induced OA rats was assessed. The treatment of UDCA was initiated on the day of MIA injection and maintained for 2 weeks. In the von Frey hair assessment test, the paw withdrawal latency (PWL) and the paw withdrawal threshold (PWT) were prolonged significantly in the inflamed hind paw of the rats given oral UDCA (50 mg/kg of body weight) compared with the placebo group (Fig. 1), demonstrating the antinociceptive property of UDCA.

Microscopic findings and modified Mankin scores in joints
As the cartilage degeneration is the main histologic feature of OA joints, the chondroprotective potential of UDCA in OA joints was investigated. The isolated knee joints from the three groups were analyzed microscopically. In the normal joints, staining with HE, Safranin O, and toluidine blue showed a smooth surface of the articular cartilage, normal cellularity, and intensive Safranin O and toluidine blue staining. In contrast, the joints from the MIA-induced OA rats showed joint space narrowing with a marked depletion of proteoglycan. These histomorphological changes in the cartilage were reduced in UDCA-treated OA rats. The overall modified Mankin scores were significantly lower in UDCA-treated rats with OA than in vehicle-treated OA rats (Fig. 2A). Subchondral bone has been suggested to play a crucial role in the pathogenesis and progression of OA (17). Involvement of subchondral bone emerged in MIA-induced OA model where the numbers of osteoclasts were increased at day 7 after MIA injection (18). Compared to the MIA-induced OA rats, the number of osteoclasts in subchondral bone lesion was significantly decreased by oral UDCA treatment (Fig. 2B).

Effects of UDCA on IL-1β and IL-6 expression in the cartilage of UDCA-treated OA rats
IL-1β and IL-6 have been revealed to be the main proinflammatory cytokines involved in the pathophysiology of OA (19). The results showed that the number of chondrocytes stained positive for IL-1β and IL-6 increased in the MIA-induced OA cartilage. The percentages of IL-1β-positive and IL-6-positive chondrocytes were significantly lower in the UDCA-treated group than in the vehicle-treated group (Fig. 3).
Reduced expression of nitrotyrosine and inducible nitric oxide synthase (iNOS) in subchondral bone region in OA rats treated with UDCA

To determine the degree of oxidative damage in the knee joints of UDCA-treated OA rats, immunohistochemistry was used to assess the expression of nitrotyrosine and iNOS on day 14 after MIA injection. Because subchondral bone changes develop 7 days after intra-articular injection of MIA, the changes in oxidative stress markers in the subchondral bone region was assessed. The expression of nitrotyrosine and iNOS increased markedly in the MIA-injected joints than in those from the control animals. The treatment with UDCA reduced the expressions of nitrotyrosine and iNOS in the subchondral bone (Fig. 4).

The inhibiting property of UDCA on catabolic factors in human OA chondrocytes

We next investigated the possible role of UDCA in modulating the expression of catabolic molecules in human OA chondrocytes. The results show that the gene expression of MMP-3, -13, and ADAMTS-5 increased after the addition of IL-1β and that the effect was reduced after the treatment with UDCA (Fig. 5A). MTT assay was used to determine whether or not chondrocytes viability is affected by UDCA treatment.
UDCA Attenuates OA Severity in MIA
Su-Jin Moon, et al.

Figure 3. Effects of UDCA on the expression of IL-1β and IL-6 in OA joints. Rats were injected with 3 mg of MIA in the right knee. UDCA was administered orally every day for 14 days after MIA injection. Immunohistochemical staining was used to identify the expression of IL-1β and IL-6 in the articular cartilage. The data are expressed as mean and error bars for 6 animals per group (Original magnification 200×). **p < 0.01 and ***p < 0.001 compared with the vehicle-treated OA group.

Figure 4. Attenuated nitrotyrosine and iNOS expression in UDCA-treated OA rats. Rats were injected with 3 mg of MIA in the right knee. UDCA was administered orally every day for 14 days after MIA injection. The knees were resected on day 14 after MIA injection. Immunohistochemical staining was used to identify the expression of nitrotyrosine and induced nitric oxide synthase (iNOS). The data are expressed as mean and error bar for 6 animals per group. (Original magnification 200×). ***p < 0.001 compared with the vehicle-treated OA group.

Figure 5. The decreased catabolic activity in human OA chondrocytes by UDCA treatment. Human articular chondrocytes from OA patients were cultured with or without IL-1β in the absence or presence of UDCA for 48 h following 24 h of starvation. The mRNA expression of catabolic factors, MMP-3, MMP-13 and ADAMTS5, was measured by quantitative real-time PCR. β-actin was used as the internal control. The cell viability was determined by MTT assay. There was no cytotoxic effect in the doses of UDCA (ranging from 0.1 to 50 μM) that were studied in this experiment. The data are expressed as dot plots with mean (bar) for three independent experiments per group. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with the untreated IL-1β-stimulated chondrocytes.
UDCA treatment up to 50 μM in human OA chondrocytes did not affect cell viability (Fig. 5B).

DISCUSSION

This study demonstrated that oral administration of UDCA attenuated the pain severity and cartilage loss, and reduced oxidative stress in subchondral bone lesions in an animal model of OA. The chondroprotective property of UDCA may be achieved by reduced expression of proinflammatory molecules and attenuated catabolic activities of chondrocytes.

Until now, the main target of OA treatment is to control chronic pain. Although cartilage degeneration is the main histological feature of OA, the extent of cartilage loss has not been positively related with pain severity in the patients with OA, MIA-induced OA rat model used in the present study mimics pain and biochemical/structural changes associated with human OA (20). Recent studies have suggested that proinflammatory cytokines such as IL-1β are implicated in pain generation in OA (21). Recent clinical studies using magnetic resonance imaging suggested that pain severity of human OA is positively correlated with the changes of subchondral bone (22,23). Interestingly, animal studies showed that nitric oxide donor significantly increased subchondral bone sclerosis during subchondral remodeling suggesting that oxidative stress could contribute to pain generation in OA. Our study demonstrating that UDCA treatment could significantly attenuated the extent of oxidative damage in subchondral bone may suggest that oxygen-radical scavenging material could be a therapeutic candidate to control pain generation in OA.

The pathophysiology of OA development and progression is complex and poorly understood. The current paradigm of OA has changed to include an active biological process of matrix degradation leading to the release of MMPs and eventually cartilage loss; both acute and chronic inflammatory processes propagate disease process (19). MMPs have been shown to degrade all components of the extracellular matrix and many studies have reported that increased activities of interstitial collagenases MMP-3 and MMP-13 in human OA cartilage as well as experimental animal models of OA (24-26). As one of catabolic factors in articular cartilage, there is ADAMTS5 that is one of aggrecanases. In conjunction with MMPs, ADAMTS5 can function to degrade extracellular matrix components of cartilage. Interestingly, ADAMTS5 is superior to MMPs in the aspect of cleaving aggrecan core protein in articular cartilage (27). Song et al. recently demonstrated that suppression of ADAMTS5 in human chondrocytes can attenuate the degradation of aggrecan in cartilage (28). In our study, the expression of MMP-3, MMP-13 and ADAMTS5 was significantly inhibited by UDCA in the IL-1β-stimulated human chondrocytes, suggesting the potential of UDCA as one of the DMOADs in OA treatment.

Continuous and low-grade oxidative stress to cells and matrix contribute to OA pathogenesis. Increased oxidative stress associated with the aging process creates chondrocytes to become more susceptible to oxidant-mediated cell death through the dysregulation of the glutathione antioxidant system (29). Therefore, reducing oxidative stress could be a novel therapeutic strategy to inhibit cartilage degeneration and to relieve debilitating pain in OA patients. Long-term treatment with UDCA markedly improved biochemical and histopathological indices of liver damage and prolonged survival (30,31). In addition to the clinical benefits of UDCA, the immunological mechanisms underlying UDCA efficacy remained uncertain. Interestingly, Okada et al. reported that UDCA can induced nuclear factor E2-related factor 2 (Nrf2) expression level in hepatocytes suggesting its potential to stimulate anti-oxidative stress systems (32). Nrf2 is a key transcription factor that plays a central role in the protection of cells against oxidative stresses. Nuclear translocation of Nrf2 up-regulates several genes encoding antioxidant proteins including heme oxygenase-1 (HO-1) and NAD(P)H (33). Taken together, UDCA may exert the anti-nociceptive and chondroprotective properties in OA animal models through the down-regulation of oxidative stress in subchondral bone lesions.

In conclusion, this is the first study demonstrating the preventive potential of UDCA in the MIA-induced OA model, UDCA reduced pain and ameliorated cartilage destruction via reducing oxidative stress and inhibiting catabolic factors implicated in disturbed extracellular matrix homeostasis of OA cartilage. Considering its antioxidant and anti-inflammatory property of UDCA, this may be a promising therapeutic option for OA.

ACKNOWLEDGEMENTS

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MEST) (No. 2012M3A9C6049783).
CONFLICTS OF INTEREST
The authors have no financial conflict of interest.

REFERENCES

1. Felson, D. T. 2006. Clinical practice. Osteoarthritis of the knee. N. Engl. J. Med. 354: 841-848.

2. Chadjichristos, C., G. Chaytor, M. Kyriakou, G. Martin, E. Renard, I. Ala-Kokko, G. Suske, B. de Crombrugghe, J. P., Pujol, and P. Galera. 2005. 5p1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes. J. Biol. Chem. 278: 39762-39772.

3. Guerne, P., A. A. Carson, and M. Lotz. 1990. IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J. Immunol. 144: 499-505.

4. Remans, P. H., C. A. Wijnhoven, M. E. Sanders, R. E. Toes, F. C. Breedveld, P. P. Tak, J. M. van Laar, and K. A. Reeedquist. 2006. CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells. Arthritis Rheum. 54: 3135-43.

5. Najim, R. A., K. E. Sharquie, and A. R. Abu-Raghif. 2007. Oxidative stress in patients with Behcett’s disease: I correlation with severity and clinical parameters. J. Dermatol. 34: 308-314.

6. Scott, J. L., C. Gabrielides, R. K. Davidson, T. E. Swingler, I. M. Clark, G. A. Wallis, R. P. Boot-Handford, T. B. Kirkwood, R. W. Taylor, and D. A. Young. 2010. Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease. Ann. Rheum. Dis. 69: 1502-1510.

7. Tiku, M. L., R. Shah, and G. T. Allison. 2000. Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation. Possible role in cartilage aging and the pathogenesis of osteoarthritis. J. Biol. Chem. 275: 20069-20076.

8. Mendes, A. F., M. M. Giamberardino, A. P. Carvalho, and M. C. Lopes. 2003. Hydrogen peroxide mediates interleukin-beta induced AP-1 activation in articular chondrocytes: implications for the regulation of iNOS expression. Cell Biol. Toxicol. 19: 203-214.

9. Tiku, M. L., G. T. Allison, K. Naik, and S. K. Karry. 2003. Malondialdehyde oxidation of cartilage collagen by chondrocytes. Osteoarthritis Cartilage 11: 159-166.

10. Pelletier, J. P., D. V. Jovanovic, V. Lascou-Coman, J. C. Fernandes, P. T. Manning, J. R. Connor, M. G. Currie, and J. Martel-Pelletier. 2000. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo. possible link with the reduction in chondrocyte apoptosis and caspase 3 level, Arthritis Rheum. 43: 1209-1209.

11. Poupon, R. E., K. D. Lindor, K. Cauch-Dudek, E. R. Dickson, R. Poupon, and E. J. Heathcote. 1997. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113: 884-890.

12. Poupon, R. 2012. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin. Res. Hepatol. Gastroenterol. 36 Suppl 1: S3-12.

13. Lapenna, D., G. Gofani, D. Festi, M. Neti, S. D. Pierdomenico, M. A. Giambardino, and F. Cucurullo. 2002. Antioxidant properties of ursodeoxycholic acid. Biochim. Biophys. Acta 1661-1667.

14. Ljubuncic, P., B. Fuhrman, J. Okline, M. Avinun, and A. Bomzon. 1996. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 39: 475-478.

15. Lukivskaia, L., Z. Zavadnik, M. Knas, and V. Buko. 2006. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv. Med. Sci. 51: 54-59.

16. Guzman, R. E., M. G. Evans, S. Bove, B. Morelko, and K. Schenk. 1982. Synthesis of cartilage matrix by mammalian chondrocytes in vitro. I. Isolation, culture characteristics, and morphology. J. Cell Biol. 93: 743-750.

17. Sharma, A. R., S. Jagga, S. S. Lee, and J. S. Nam, 2013. Interplay between Cartilage and Subchondral Bone Contributing to Pathogenesis of Osteoarthritis. Int. J. Mol. Sci. 14: 19805-19830.

18. Guzman, R. E., M. G. Evans, S. Bove, B. Morelko, and K. Kilgore. 2003. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femoral joint: an animal model of osteoarthritis. Toxicol. Pathol. 31: 619-624.

19. Kapoor, M., J. Martel-Pelletier, D. Lajeunesse, J. P. Pelletier, and H. Fahimi, 2011. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis, Nat. Rev. Rheumatol. 7: 33-42.

20. Kobayashi, K., R. Imazumi, H. Sumichika, H. Tanaka, M. Goda, A. Fukunari, and H. Komatsu. 2003. Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats, J. Vet. Med. Sci. 65: 1195-1199.

21. Chevalier, X., B. Giraudet, T. Conrozier, J. Marliere, P. Kiefer, and P. Gouillie, 2005. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study, J. Rheumatol. 32: 1317-1323.

22. Singh, S., A. Avasthi, A. Mishra, A. Singh, S. Agarwal, and R. N. Srivastava, 2011. Is radiology a determinant of pain, stiffness, and functional disability in knee osteoarthritis? A cross-sectional study, J. Orthop. Sci. 16: 719-725.

23. Gotofana, S., B. T. Wyman, O. Benichou, D. Dreher, M. Nevitt, J. Gardiner, W. Wirth, W. Hitzl, C. K. Kwoh, F. Eckstein, and R. B. Frobell, 2013. Relationship between knee pain and the presence, location, size and phenotype of femoral osteoarthritic cartilage: an MRI study, Osteoarthritis Cartilage 21: 1214-1222.

24. Dean, D. D., W. Azzo, J. Martel-Pelletier, J. P. Pelletier, and J. F. Woessner, Jr. 1987. Levels of metalloproteases and tissue inhibitor of metalloproteases in human osteoarthritic cartilage, J. Rheumatol. 14 Spec No: 43-44.

25. Huebner, J. L., I. G. Otterness, E. M. Freund, B. Caterson, Sujin Moon, et al.
and V. B. Kraus, 1998, Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. Arthritis Rheum., 41: 877-890.

26. Tanaka, S., C. Hamanishi, H. Kikuchi, and K. Fukuda, 1998, Factors related to degradation of articular cartilage in osteoarthritis: a review, Semin. Arthritis Rheum., 27: 392-399.

27. Durigova, M., H. Nagase, J. S. Mort, and P. J. Roughley, 2011, MMPs are less efficient than ADAMTS5 in cleaving aggrecan core protein, Matrix Biol., 30: 145-153.

28. Song, R. H., M. D. Tortorella, A. M. Malfait, J. T. Alston, Z. Yang, E. C. Arner, and D. W. Griggs, 2007, Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5, Arthritis Rheum., 56: 575-585.

29. Carlo, M. D. Jr, and R. F. Loeser, 2003, Increased oxidative stress with aging reduces chondrocyte survival: correlation with intracellular glutathione levels, Arthritis Rheum., 48: 3419-3430.

30. Poupon, R. E., B. Balkau, E. Eschwege, and R. Poupon, 1991, A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis, UDCA-PBC Study Group, N. Engl. J. Med., 324: 1548-1554.

31. Corpechot, C., F. Carrat, A. Bahar, Y. Chretien, R. E. Poupon, and R. Poupon, 2005, The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis, Gastroenterology, 128: 297-303.

32. Okada, K., J. Shoda, K. Taguchi, J. M. Maher, K. Ishizaki, Y. Inoue, M. Ohtsuki, N. Goto, K. Takeda, H. Utsunomiya, K. Oda, E. Warabi, T. Ishii, K. Osaka, I. Hyodo, and M. Yamamoto, 2008, Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidant stress systems in mice, Am. J. Physiol. Gastrointest. Liver Physiol., 295: G735-747.

33. Kim, J., Y. N. Cha, and Y. J. Surh, 2010, A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders, Mutat. Res., 690: 12-23.